High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière's disease: a case series

scientific article published on 29 May 2011

High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière's disease: a case series is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1034271844
P356DOI10.1007/S00405-011-1647-2
P698PubMed publication ID21626121

P50authorChristine AdrionQ50285744
P2093author name stringMichael Strupp
Ulrich Mansmann
Klaus Jahn
Franziska Lezius
P2860cites workBetahistine for Menière's disease or syndrome.Q30661909
Betahistine: a retrospective synopsis of safety dataQ31069695
Clinical and epidemiological study of vertigo at an outpatient clinic.Q35672344
Pathophysiology of Meniere's syndrome: are symptoms caused by endolymphatic hydrops?Q36033980
Long-term prophylactic treatment of attacks of vertigo in Menière's disease--comparison of a high with a low dosage of betahistine in an open trialQ46637476
Psychiatric comorbidity in different organic vertigo syndromes.Q51892852
Psychological assessment of patients with Menière's disease.Q51912183
The interrelations of migraine, vertigo, and migrainous vertigo.Q52966238
Episodic vertigo related to migraine (90 cases): vestibular migraine?Q53341865
Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière's disease. American Academy of Otolaryngology-Head and Neck Foundation, IncQ72060598
Meniere's diseaseQ81733714
P433issue8
P304page(s)1237-1240
P577publication date2011-05-29
P1433published inEuropean Archives of Oto-Rhino-LaryngologyQ2624005
P1476titleHigh-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière's disease: a case series
P478volume268

Reverse relations

cites work (P2860)
Q28081399Association of cinnarizine and betahistine in prophylactic therapy for Ménière's disease with and without migraine
Q55407927Betahistine Treatment in a Cat Model of Vestibular Pathology: Pharmacokinetic and Pharmacodynamic Approaches.
Q34321223Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in guinea pigs in vivo
Q89729736Betahistine, prevents kindling, ameliorates the behavioral comorbidities and neurodegeneration induced by pentylenetetrazole
Q45502246Cardinal symptom vertigo from the neurologist's perspective
Q43925111Dizziness from the viewpoint of otorhinolaryngology
Q34035274Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of Ménière's disease: a 10-year experience
Q56672452Effect of standard-dose Betahistine on endolymphatic hydrops: an MRI pilot study
Q35026152Effects and safety profile of betahistine in patients in the Russian contingent of OSVaLD, an open-label observational study in vestibular vertigo
Q34661826Effects and tolerability of betahistine in patients with vestibular vertigo: results from the Romanian contingent of the OSVaLD study.
Q28602238Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial)
Q91754507European Position Statement on Diagnosis, and Treatment of Meniere's Disease
Q93378595Good Clinical Approach: Delphi Consensus for the Use of Betahistine in Menière's Disease
Q52659022Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study.
Q26827285The link between allergy and Menière's disease
Q37118909The treatment and natural course of peripheral and central vertigo
Q47989461Treatment of Menière's Disease
Q44889838Vertigo and dizziness: the neurologist's perspective